Most Read News

Domestic patient volumes rose over 15% year-on-year in the March quarter, helping to offset a sharp 53% decline in medical tourism from Bangladesh

Revenue increased 11% YoY to ₹265.30 crore from ₹240 crore in Q4 FY24, suggesting healthy sales traction.

The company has a strong foothold in the Indian pharma market as well as in the international market where it sells its products in more than 55 countries

Revenue from operations in the quarter was at ₹534 crore, a 13% increase from ₹471 crore in Q4 FY24

Revenue from operations was down by 20.3% y-o-y to ₹1,360.9 crore in Q4 FY25 from ₹1,708.2 crore in Q4 FY24

Annual income at the company also grew by a big margin of ₹31,724 crore in FY25 from ₹29,002 crore in FY24, up 9.4% on yearly basis

Revenue from operations was at ₹767.5 crore, 12.7% higher than ₹681 crore reported in the March quarter of FY24

An EBITDA of ₹498 crore at Q4 FY25 shrank by 6.4% over ₹532.2 crore in the corresponding quarter last year.

Its operating revenue in the quarter also stayed nearly flat at ₹2,055 crore as against ₹2,110 crore in Q4 FY24

RBI noticed that Union Bank did not transfer the eligible unclaimed amounts to the DEAF within the prescribed time, violating the rules in force.